All terms in BAO
| Label | Id | Description |
|---|---|---|
| hepatitis C | DOID_1883 | [A viral infectious disease that results_in inflammation located_in liver, has_material_basis_in Hepatitis C virus, which is transmitted_by blood from an infected person enters the body of an uninfected person. The infection has_symptom fever, has_symptom fatigue, has_symptom loss of appetite, has_symptom nausea, has_symptom vomiting, has_symptom abdominal pain, has_symptom clay-colored bowel movements, has_symptom joint pain, and has_symptom jaundice.] |
| paralytic squint | DOID_10863 | |
| Kuhnt-Junius degeneration | DOID_10873 | |
| age related macular degeneration | DOID_10871 | [A degeneration of macula and posterior pole that is characterized by a loss of vision in the center of the visual field (the macula) resulting from damage to the retina and resulting in blurring of the sharp central vision.] |
| Drosophila melanogaster | NCBITaxon_7227 | |
| Vd | BAO_0003040 | [Volume of Distribution is defined as the theoretical volume in which the total drug administered would need to be distributed to produce the concentration that is observed in plasma. Measured as the total amount of drug in the body divided by the concentration of drug in the plasma.] |
| Vdss | BAO_0003041 | [The theoretical volume in which the total drug administered would need to be distributed to produce the concentration that is observed in plasma at steady state i.e when the rate of change of amount of drug in the body is zero. VdSS is proportional to the amount of drug in the body versus the plasma concentration of the drug at steady state (pseudo-equilibrium).] |
| F | BAO_0003042 | [Bioavailability is a subcategory of absorption and is the fraction (or %) of unchanged drug that reaches the systemic circulation, thereby accessing the site of action. It is usually determined as the ratio of AUC(oral)/AUC(iv).] |
| epidemic pleurodynia | DOID_10882 | [A viral infectious disease that results_in necrosis located_in intercostal muscle, has_material_basis_in Human enterovirus B. The infection has_symptom severe chest pain, has_symptom fever, has_symptom malaise, has_symptom pleuritis, and has_symptom headache.] |
| herpangina | DOID_10883 | [A viral infectious disease that results_in infection located_in mouth, has_material_basis_in Human coxsackievirus A16, has_material_basis_in Human enterovirus 71, has_material_basis_in group B coxsackievirus, or has_material_basis_in echoviruses, which are transmitted_by ingestion of food contaminated with feces, transmitted_by contact with pharyngeal secretions, or transmitted_by droplet spread of oronasal secretions. The infection has_symptom fever, has_symptom sore throat, and has_symptom lesions in the back area of the mouth, particularly the soft palate or tonsillar pillars.] |
| hand, foot and mouth disease | DOID_10881 | [A viral infectious disease that results_in infection located_in skin, has_material_basis_in Human coxsackievirus A16 or has_material_basis_in Human enterovirus 71, which are transmitted_by contaminated fomites, and transmitted_by contact with nose and throat secretions, saliva, blister fluid and stool of infected persons. The infection has_symptom fever, has_symptom poor appetite, has_symptom malaise, has_symptom sore throat, has_symptom painful sores in the mouth, and has_symptom skin rash on the palms of the hands and soles of the feet.] |
| kinase competitive binding method | BAO_0003032 | |
| mobility shift assessment method | BAO_0003033 | |
| MIC50 | BAO_0003035 | [The lowest concentration of an antimicrobial agent required to inhibit the growth of 50% of organisms.] |
| ED50 | BAO_0003036 | [It is the dose that produces an effect in 50% of the tested population, or the dose required to produce half-maximal response.] |
| Tmax | BAO_0003037 | [The time required for a drug to reach maximum concentration in plasma (Cmax) following administration.] |
| alcoholic psychosis | DOID_252 | |
| alcohol-induced mental disorder | DOID_251 | |
| pA2 | BAO_0003038 | [The negative logarithm (log10) of the molar concentration of antagonist which requires the agonist concentration to be doubled in order to achieve the original response.] |
| giant cell reparative granuloma | DOID_1866 |